Repligen enters into $125 million 364-day bridge term loan

By Rebecca Melvin

New York, April 26 – Repligen Corp. has entered into a commitment letter regarding a $125 million senior secured 364-day term loan facility, concurrently with a stock purchase agreement, according to an 8-K filing with the Securities and Exchange Commission.

JPMorgan Chase Bank will act as the sole administrative agent, sole lead arranger and sole bookrunner of the bridge facility.

The proceeds may be used for the payment of the cash consideration of the execution of the purchase agreement.

Waltham, Mass.-based Repligen is a bioprocessing company focused on the development, production and commercialization of products used in the production of monoclonal antibodies, recombinant proteins and vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.